ACS Infectious Diseases

Addition/Correction

Cite This: *ACS Infect. Dis.* 2019, 5, 1042−1043

pubs.acs.org/journal/aidcbc

Correction to "Elucidation of a Novel Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy"

Bryna L. Fitzgerald, M. Nurul Islam, Barbara Graham, Sebabrata Mahapatra, Kristofor Webb, W. Henry Boom, Stephanus T. Malherbe, Moses L. Joloba, John L. Johnson, Jill Winter, Gerhard Walzl, and John T. Belisle*

ACS Infect. Dis. **2019**, 5 (3), 353−364. DOI: 10.1021/acsinfecdis.8b00241

Supporting Information

Figure 2 has been updated with corrected structures in parts D, F, and H.



Figure 2. Enzymatic deglycosylation and MS confirmation of core 1 glycosylation. MF 874.3547 untreated (A, C, E, G, I) and treated with α2-3,6,8 neuraminidase and *O*-glycosidase (B, D, F, H, J) were analyzed by LC−MS, and the spectra were evaluated by extracted ion chromatogram (EIC) for intact glycopeptide (A and B), the glycopeptide minus Neu5Ac (C and D), the Hex−HexNAc disaccharide (E and F), Neu5Ac (G and H), and the deglycosylated putative diamino acid S/TX (I and J). The * in panel C indicates a low level of the glycopeptide minus Neu5Ac (*m*/*z* 584.2661) present in the undigested sample. Note the level of this product was considerably higher following digestion (G). In source fragmentation of SLC1G yielded the *m*/*z* 584.2661 product (# in panel C) at the same retention time as the undigested glycopeptide.

Figure 3 has been updated with corrected structure in part E.



Figure 3. Confirmation of seryl-leucine peptide and SLC1G structure. EIC for *m*/*z* 219.1328 in LC−MS spectra of α2-3,6,8 neuraminidase and *O*-glycosidase treated MF 874.3547 (A) and seryl-leucine standard (C). MS/MS of *m*/*z* 219.1328 from α2-3,6,8 neuraminidase and *O*-glycosidase treated MF 874.3547 (B) and the seryl-leucine standard (D). The confirmed structure of Neu5Acα2-3Galβ1-3GalNAcα1-O-SerLeu for MF 874.3547 (E).

Received: February 19, 2019
Published: March 13, 2019

DOI: 10.1021/acsinfecdis.9b00068
ACS Infect. Dis. 2019, 5, 1042−1043

Figures S3 in the Supporting Information has been updated with corrected structures. The corrected Supporting Information file is with this Correction.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsinfecdis.9b00068.

Figure S1, presence of SLC1G in TB patients and healthy controls; Figure S2, demonstration of Neu5Ac with an α2-3 linkage as the terminal sugar of SLC1G; Figure S3, activity of α2-3 neuraminidase or α2-3,6,8 neuraminidase and *O*-glycosidase on commercial oligosaccharide standards; Figure S4, LC−MS chromatograms of diamino acid standards and of α2-3,6,8 neuraminidase and *O*-glycosidase treated SLC1G; Figure S5, fold change of SLC1G levels during treatment and SLC1G abundance associations to GeneXpert and PETCT measurements based on individual patients; Table S1, transcript levels for potential SLC1G source protein in Catalysis Study patients (PDF)

DOI: 10.1021/acsinfecdis.9b00068
ACS Infect. Dis. 2019, 5, 1042−1043